GSK’s Blenrep (belantamab mafodotin-blmf) Receives the US FDA’s Approval as a Monotherapy Treatment for Multiple Myeloma

 GSK’s Blenrep (belantamab mafodotin-blmf) Receives the US FDA’s Approval as a Monotherapy Treatment for Multiple Myeloma

GSK and Innoviva’s Trelegy Ellipta (FF/UMEC/VI) Receive the US FDA’s Approval for Asthma and COPD

Shots:

  • The approval is based on a pivotal study, DREAMM-2 assessing Blenrep (2.5 mg/kg, q3w) in 218 patients with relapsed or refractory multiple myeloma who had actively progressing disease that had worsened despite current SoC
  • Results: Blenrep demonstrated an ORR (31%), DoR not reached at the 6-mos. analysis, but 73% of responders had a DoR ≥ 6 mos. Continued approval for this indication depends upon verification and description of clinical benefit in confirmatory trials
  • Blenrep (belantamab mafodotin-blmf) is an antibody drug conjugate comprising a humanised anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F. Blenrep is the 1st anti-BCMA therapy approved globally and 5th major medicine approval for GSK in 2020

Click here ­to­ read full press release/ article | Ref: Twitter | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post